The first GIP & GLP-1 receptor agonist for T2D treatment

Introduction

Build awareness on Mounjaro - the first GIP & GLP-1 receptor agonist through an engaging discussion with investigators covering:
• MoA
• Phase Ill SURPASS trial program.

Objectives

.

This Course For :

Physician ( Endocrinology & Metabolism )
Resident / Fellow ( Endocrinology & Metabolism )

Speaker


Note : This content is sponsored and approved by Eli Lilly and company (Lilly). This content is intellectual property of Lilly and its reproduction needs Lilly prior permission.

  • 05 Jul 2023    To    05 Jul 2023
  • 10:00 PM  To  11:00 PM
  • Certificate Available
  • Online
  • 4
  Add to Calendar 07/05/2023 10:00 PM 07/05/2023 11:00 PM Asia/ Riyadh The first GIP & GLP-1 receptor agonist for T2D treatment The first GIP & GLP-1 receptor agonist for T2D treatment https://medicalacademy.org/portal/event/view/1978
The first GIP & GLP-1 receptor agonist for T2D treatment